2azb: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 2azb |SIZE=350|CAPTION= <scene name='initialview01'>2azb</scene>, resolution 2.03Å | |PDB= 2azb |SIZE=350|CAPTION= <scene name='initialview01'>2azb</scene>, resolution 2.03Å | ||
|SITE= | |SITE= | ||
|LIGAND= | |LIGAND= <scene name='pdbligand=PHQ:FORMIC+ACID+BENZYL+ESTER'>PHQ</scene> | ||
|ACTIVITY= [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] | |ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] </span> | ||
|GENE= pol ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 Human immunodeficiency virus 1]) | |GENE= pol ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 Human immunodeficiency virus 1]) | ||
|DOMAIN= | |||
|RELATEDENTRY=[[2az8|2AZ8]], [[2az9|2AZ9]], [[2azc|2AZC]] | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2azb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2azb OCA], [http://www.ebi.ac.uk/pdbsum/2azb PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2azb RCSB]</span> | |||
}} | }} | ||
| Line 30: | Line 33: | ||
[[Category: Stout, C D.]] | [[Category: Stout, C D.]] | ||
[[Category: Torbett, B E.]] | [[Category: Torbett, B E.]] | ||
[[Category: hiv-1 | [[Category: f53l]] | ||
[[Category: hiv-1]] | |||
[[Category: inhibitor]] | |||
[[Category: m46i]] | |||
[[Category: protease]] | |||
[[Category: tl-3]] | |||
[[Category: v82a]] | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 01:59:20 2008'' | ||
Revision as of 01:59, 31 March 2008
| |||||||
| , resolution 2.03Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | |||||||
| Gene: | pol (Human immunodeficiency virus 1) | ||||||
| Activity: | HIV-1 retropepsin, with EC number 3.4.23.16 | ||||||
| Related: | 2AZ8, 2AZ9, 2AZC
| ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
HIV-1 Protease NL4-3 3X mutant in complex with inhibitor, TL-3
OverviewOverview
The development of resistance to anti-retroviral drugs targeted against HIV is an increasing clinical problem in the treatment of HIV-1-infected individuals. Many patients develop drug-resistant strains of the virus after treatment with inhibitor cocktails (HAART therapy), which include multiple protease inhibitors. Therefore, it is imperative that we understand the mechanisms by which the viral proteins, in particular HIV-1 protease, develop resistance. We have determined the three-dimensional structure of HIV-1 protease NL4-3 in complex with the potent protease inhibitor TL-3 at 2.0 A resolution. We have also obtained the crystal structures of three mutant forms of NL4-3 protease containing one (V82A), three (V82A, M46I, F53L) and six (V82A, M46I, F53L, V77I, L24I, L63P) point mutations in complex with TL-3. The three protease mutants arose sequentially under ex vivo selective pressure in the presence of TL-3, and exhibit fourfold, 11-fold, and 30-fold resistance to TL-3, respectively. This series of protease crystal structures offers insights into the biochemical and structural mechanisms by which the enzyme can overcome inhibition by TL-3 while recovering some of its native catalytic activity.
About this StructureAbout this Structure
2AZB is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
ReferenceReference
Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3., Heaslet H, Kutilek V, Morris GM, Lin YC, Elder JH, Torbett BE, Stout CD, J Mol Biol. 2006 Mar 3;356(4):967-81. Epub 2005 Dec 20. PMID:16403521
Page seeded by OCA on Mon Mar 31 01:59:20 2008